Tissue-restricted T cell alloresponses across HLA barriers: Selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs

Bone Marrow Transplantation

Volumn 32, Issue 4, 2003, Pages 371-378

  Fujiwara, H ^a   Sconocchia, G ^a   Melenhorst, J ^a   Eniafe, R ^a   Nakamura, R ^a   Hensel, N ^a   Barrett, A J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cytotoxic T lymphocytes; HLA mismatched; Leukemia restriction; Stem cell transplant

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; INTERLEUKIN 2 RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOIMMUNITY; ARTICLE; BASE MISPAIRING; CELL GROWTH; CELL SELECTION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING CELL; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW MEASUREMENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOTYPE; HISTOCOMPATIBILITY GENE; HUMAN; LEUKEMIA CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

ANTIGENS, CD57; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL LINE, TUMOR; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HAPLOTYPES; HLA ANTIGENS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTES, MONONUCLEAR; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 0041386208     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704142     Document Type: Article

References (36)

1. Henslee-Downey PJ, Abhyankar SH, Parrish RS, Pati AR. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89: 3864-3872.
2. Henslee-Downey P. Mismatched bone marrow transplantation. Curr Opin Oncol 1995; 7: 115-121.
3. Szydlo R, Goldman JM, Klein JP, Gale RP. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767-1777.
4. Sykes M, Sachs DH. Genetic analysis of the anti-leukemic effect of mixed allogeneic bone marrow transplantation. Transplant Proc 1989; 21: 3022-3024.
5. Aizawa S, Sado T. Graft-versus-leukemia effect in MHC compatible and- incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice. Transplantation 1991; 52: 885-889.
6. Versa F, Tabilio A, Velardi A, Cunningham I. Treatment of high-risk acute leukemia with T-cell depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
7. Sykes M, Preffer F, MaAfee S, Saidman SL. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755-1759.
8. Green A, Clarke E, Hunt L, Canterbury A. Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome. Blood 1999; 94: 2236-2246.
9. Mattsson J, Uzunel M, Remberger M, Tammik L. Poor immune reconstitution after four or five major HLA antigen mismatched T cell-depleted allogeneic and autologous stem cell transplantation. Clin Exp Immunol 2001; 123: 162-169.
10. Gaschet J, Trevino MA, Cherel M, Vivien R. HLA-target antigens and T-cell receptor diversity of activated T cells invading the skin during acute graft-versus-host disease. Blood 1996; 87: 2345-2353.
11. Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant 2001; 7: 620-630.
12. Leung WH, Turner V, Richardson SL, Benaim E. Effect of HLA class I or class II incompatibility in pediatric marrow transplantation from unrelated and related donors. Hum Immunol 2001; 62: 399-407.
13. Bonnet D, Warren EH, Greenberg PD, Dick JE. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1998; 96: 8639-8644.
14. Gao L, Bellantuono I, Elsasser A, Marley SB et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198-2203.
15. Molldrem JJ, Lee PP, Wang C, Felio K. Evidence that specific T lymphocyte may participate in the elimination of chronic myelogenous leukemia. Nature Med 2000; 6: 1018-1023.
16. Norbury LC, Clark RE, Christmas SE. b3a2 BCR-ABL fusion peptides are targets for cytotoxic T cells in chronic myeloid leukemia. Br J Haematol 2000; 109: 616-621.
17. Spiro RC, DeMartino JL, Boto W, Lazarus H. Comparison of membrane proteins of Burkitt's lymphoma and EBV-transformed B lymphoblast cell lines and Con A-activated T lymphocytes and T lymphoblast cell lines. Leuk Res 1979; 3: 315-327.
18. + lymphocyte populations. Br J Haematol 2000; 112: 189-194.
19. Molldrem JJ, Clave E, Jiang YZ, Mavroudis D. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997; 90: 2529-2534.
20. Hensel N, Agarwala V, Jiang YZ, Mavroudis D. A technique for dual determination of cytotoxic and helper lymphocyte precursor frequency by a miniaturized dye release method. Bone Marrow Transplant 1999; 23: 71-78.
21. Wang XM, Terasaki PI, Rankin GWJ, China D. A new microcellular cytotoxicity test based on Calcein AM release. Hum Immunol 1993; 37: 264-270.
22. Chen RL, Reynolds CP, Seeger RC. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Cancer Immunol Immunother 2000; 48: 603-612.
23. Sheehy ME, McDermott AB, Furlan SN, Klenerman P. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 2001; 249: 99-110.
24. Currier JR, Deulofeut H, Barron KS, Kehn PJ. Mitogens, superantigens, and nominal antigens elicit distinctive patterns of TCRB CDR3 diversity. Hum Immunol 1996; 48: 39-51.
25. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994; 76: 287-299.
26. Young NT, Roelen DL, Wood K, Welsh KI. Primary alloreactive cytotoxic T-lymphocytes are not commonly restricted by self-HLA class I antigens. Hum Immunol 1996; 50: 38-46.
27. Sadovnikova E, Stauss HJ. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc Natl Acad Sci USA 1996; 93: 13114-13118.
28. Sadovnikova E, Jopling LA, Soo KS, Stauss HJ. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 1998; 28: 193-200.
29. + early progenitor cells. Blood 1997; 90: 1083-1090.
30. Mutis T, Verdijk R, Schrama E, Esdendam B. Feasibility of immunotherapy of relapsed leukemia with ex vivo -generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93: 2336-2341.
31. Mutis T, Blokland E, Kester M, Schrama E. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. Blood 2002; 100: 547-552.
32. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002; 360: 130-137.
33. Montagna D, Yvon E, Calcaterra V, Comoli P. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood 1999; 93: 3550-3557.
34. Mavroudis DA, Dermime S, Molldrem J, Jiang YZ. Specific depletion of alloreactive T cells in HLA- identical siblings: a method for separating graft-versus-host and graft-versus-leukemia reactions. Br J Haematol 1998; 101: 565-570.
35. Falkenburg JH, Wafelman AR, Joosten P, Smit WM. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201-1208.
36. Lowdell MW, Lamb L, Hoyle C, Velardi A. Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukemias. Br J Haematol 2001; 114: 11-24.